Medical imaging technologies can facilitate drug discovery, efficacy evaluation, and translation into the clinic. Now a maturing platform, molecular imaging is the catalyst for a new standard of how drug candidates are evaluated and advanced into trials.
By providing clinically translatable biomarkers as an accompaniment to standard measures of response, imaging leverages and amplifies the valuable data gathered during earlier stages of discovery and efficacy evaluation. A significant determinant of the clinical applicability of the obtained biomarker data is preclinical models that it is derived from. As a cornerstone of modern cancer drug discovery, a diverse array of preclinical cancer models are available, each with unique advantages and shortcomings.